General
Preferred name
PF-06700841
Synonyms
PF-06700841, Brepocitinib ()
PF-06700841 tosylate ()
BREPOCITINIB ()
BREPOCITINIB TOSYLATE ()
Pf-06700841 ()
PF-06700841-15 ()
P&D ID
PD120281
CAS
1883299-62-4
2140301-96-6
Tags
available
drug candidate
Drug indication
Psoriasis vulgaris
Immune System disease
Asthma
atopic eczema
Plaque psoriasis
Drug Status
investigational
Max Phase
3.0
1.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Brepocitinib (PF-06700841) is a dual Janus kinase 1 (JAK1) and TYK2 inhibitor . It is proposed for treating autoimmune and other inflammatory conditions. Brepocitinib is a Type 1 ATP site inhibitor.
(GtoPdb)
DESCRIPTION
PF-06700841 is an inhibitor of tyrosine-protein kinases.
(Enamine Bioactive Compounds)
DESCRIPTION
PF-06700841 is a potent and selective inhibitor of TYK2 and JAK1. It has the potential to treat plaque psoriasis and lupus erythematosus.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
8
BOC Sciences Bioactive Compounds
ChEMBL Drugs
DrugBank
DrugMAP
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
PKIDB
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
20
Molecular Weight
389.18
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
2
cLogP
1.79
TPSA
79.18
Fraction CSP3
0.56
Chiral centers
3.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Source data
